MoonLake Immunotherapeutics
Financing
SEC filings to 2026-10-05 · every row opens its filingShares on issue
85.1M
on 2026-08-01, from 73.6M on 2026-05-01 10-Q ↗
a raise that quarter, at its price
Newest
No limit
S-3ASR of 2026-08-10. An automatic shelf: the form sets no dollar limit. Sales under the at-the-market programme filed with it are not stated apart. S-3ASR ↗
$300.0M
Leerink Partners, agreement of 2023-08-31. No at-the-market sales statement read from a 10-Q or 10-K. S-3ASR ↗
Warrants
The 10-Q filed 2026-08-10 is not read yet.
Cash
9.5 quarters
$537.0M on 2026-06-30 ÷ $56.3M a quarter of operating cash used, the average of four quarters. 10-Q ↗
| Date | What | Shares | Price | Gross | Filing |
|---|---|---|---|---|---|
| 2026-06-23 | Public offering incl. 1.00M pre-funded | 10,000,000 | $20.00 | $200.0M | 424B5 ↗ |
| 2025-11-05 | Public offering | 7,142,857 | $10.50 | $75.0M | 424B5 ↗ |
Also on file: $25.0M term loan, 2026-02-22 8-K ↗